Polbionica
Polbionica is a Polish 3D bioprinting biotech that develops proprietary bioinks, a bioreactor platform, and bioprinting services for researchers, pharmaceutical preclinical teams, and clinicians, with its flagship Bionic Pancreas-ATMP advancing toward clinical trials for type 1 diabetes.
- Company typePrivate
- Founded2019
- HeadquartersZielona Góra, Poland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Polbionica does
Polbionica is a privately held Polish research center and biotech company founded in 2019 and headquartered in Zielona Góra, with a secondary office in Warsaw. The company specializes in 3D bioprinting and biofabrication, developing a vertically integrated ecosystem of proprietary bioinks (TintBionic, Printiss, CleanCure), a photo-curing platform (BionicCure UV-Vis lamp), a dynamic bioreactor system (ResearchLine 3D Flow & Culture), recombinant structural proteins (p-SE17, p-RE15), and custom 3D bioprinting services. Manufacturing is conducted under ISO 13485 quality management, supporting batch-to-batch reproducibility required by research and clinical customers.
The company's flagship program is the Bionic Pancreas-ATMP — described as the world's first functional organ bioprinted from living cells, with full vascularization and physiological insulin/glucagon secretion capability — targeting type 1 diabetes and chronic pancreatitis. Preclinical studies have been completed and the company is preparing for clinical trials, positioning the asset as a future therapeutic revenue stream under ATMP regulatory pathways. The platform also supports 3D bioprinted liver tissue models and personalized tissue constructs for drug testing and preclinical research applications.
Commercially, Polbionica operates a B2B sales-led model selling bioinks and biomaterials (one-time consumables), laboratory capital equipment (bioreactors, UV-Vis lamps), and bespoke 3D bioprinting services directly through its company website to academic researchers, pharmaceutical preclinical teams, and clinicians. The horizontal segmentation across regenerative medicine, drug development, and clinical end-markets diversifies exposure but no named customer logos or revenue figures are publicly disclosed. Non-dilutive funding has come via two European Commission Seals of Excellence (Horizon 2020 SME Instrument in 2020 and Horizon Europe EIC Accelerator in 2023), while the AuRes automatic resuscitator signals broader medtech ambition beyond bioprinting.
Polbionica firmographics
Firmographics- Name
- Polbionica
- Legal name
- Polbionica
- Website
- https://polbionica.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Polbionica is a Polish 3D bioprinting biotech that develops proprietary bioinks, a bioreactor platform, and bioprinting services for researchers, pharmaceutical preclinical teams, and clinicians, with its flagship Bionic Pancreas-ATMP advancing toward clinical trials for type 1 diabetes.
- Ownership category
- akta.pro rank
Polbionica industry classification
Industry- Product category
- 3D Bioprinting & Tissue Engineering
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- 3D Bioprinting & Biofabrication (HLAAAGAC)
- akta.pro secondary industry
- Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG)
Keywords
Where Polbionica is headquartered
LocationHeadquarters
- HQ city
- Zielona Góra
- HQ country
- Poland
- HQ region
- Europe
Offices2 records
Markets served
Polbionica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Bioinks and Biomaterials Sales: Polbionica manufactures and sells a comprehensive portfolio of proprietary bioinks and biomaterials including TintBionic, Printiss, CleanCure, LAP photoinitiator, and recombinant proteins (p-SE17, p-RE15). Products are available through the company website catalog with per-unit pricing. ISO 13485 certified manufacturing supports product quality and reproducibility.
- Laboratory Devices Sales: Sale of laboratory equipment including the ResearchLine Bioreactor 3D Flow & Culture and BionicCure UV-Vis lamps. These are capital equipment purchases for research laboratories and institutions.
- 3D Bioprinting Services: Specialized bioprinting services including 3D bioprinted organoids and tissue models, cellular scaffold bioprinting, and 3D bioprinting consulting services. Services target researchers and clinicians requiring custom bioprinting solutions.
- Bionic Pancreas-ATMP Therapeutic Development: Following successful preclinical studies, the company is preparing for clinical trials for the Bionic Pancreas-ATMP as a novel therapeutic for type 1 diabetes and chronic pancreatitis. This represents a future therapeutic revenue stream.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Polbionica product offering
Product offeringCore offering
Polbionica develops and manufactures a vertically integrated ecosystem for 3D bioprinting, including proprietary bioink lines (TintBionic, CleanCure, Printiss), laboratory devices (ResearchLine bioreactor, BionicCure UV-Vis lamp, LAP photoinitiator), recombinant proteins (p-SE17, p-RE15), and 3D bioprinting services for tissue/organoid fabrication. Its flagship program is the Bionic Pancreas-ATMP, a fully vascularized bioprinted organ targeting type 1 diabetes and chronic pancreatitis. Products are manufactured under ISO 13485 quality management for researchers, clinicians, and pharmaceutical customers.
Differentiator
Problem solved
Functional benefit
Brands
- TintBionic®: Advanced biomaterials product line for biofabrication and 3D bioprinting, including GELMA 50, GELMA 80, ALGMA, HAMA, CHIMA, and GELMA-G variants.
- Printiss®
- CleanCure™
- BionicCure™
- ResearchLine™
- Bionic Pancreas-ATMP®
- Hybrid Recombinant Proteins
Products and services
- TintBionic Bioink Line
Quantifiable outcome
- Full vascularization and physiological insulin and glucagon secretion demonstrated in Bionic Pancreas-ATMP preclinical studies
- +1 more outcomes
Companies that use Polbionica
Customer profileSegments3 records
Ideal customer profiles3 records
Polbionica technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Polbionica partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights6 records
Polbionica competitors and assessment
Company assessmentEmerging players
- TissUse: German company developing multi-organ-on-chip platforms using tissue engineering approaches. Adjacent to Polbionica's bioreactor and 3D tissue model offerings, with overlapping customer base in preclinical drug testing applications.
- Cyfuse Biomedical: Japanese regenerative medicine company using 3D bioprinting to produce cellular constructs for clinical applications. Comparable in bridging proprietary biofabrication technology with therapeutic tissue development, though focused on different tissue types.
- Pandorum Technologies: India-based biotech developing 3D bioprinted tissues and organoids, including cornea and liver tissues. Comparable emerging player combining bioink development with therapeutic tissue programs targeting specific organ indications.
- Modern Meadow: Biofabrication company leveraging tissue engineering and bio-based materials, initially focused on sustainable materials with emerging therapeutic applications. Comparable in applying biofabrication technology beyond pure research tools toward commercial therapeutic products.
Direct peers
- CollPlant Biotechnologies: Israel-based regenerative medicine company developing bioinks and tissue products from recombinant human collagen. Direct competitor in tissue-specific bioinks for 3D bioprinting and biofabrication applications.
- RegenHU: Swiss manufacturer of bioprinters and biofabrication platforms for tissue engineering and regenerative medicine. Comparable to Polbionica's hardware offering (ResearchLine bioreactor, BionicCure UV-Vis lamp) in providing specialized bioprinting equipment to research labs.
- BICO (CELLINK): BICO (parent of CELLINK) is the dominant commercial player in bioprinters, bioinks, and lab automation for 3D cell culture. Directly competes with Polbionica's bioinks and bioprinting equipment, but at substantially larger scale across broader life science applications.
- Aspect Biosystems: Canadian bioprinting company developing physiologically relevant tissues for therapeutic and drug discovery applications. Directly comparable in combining proprietary bioprinting technology with a pipeline of tissue therapeutics, including endocrinology-focused programs.
- Advanced BioMatrix: Specialized bioink and biomaterials supplier for 3D bioprinting and tissue engineering research. Directly competes with Polbionica's TintBionic and Printiss product lines in the research bioink catalog market.
- Organovo: Pioneer in 3D bioprinted human tissues for preclinical drug discovery and therapeutic applications. Closest direct peer to Polbionica in targeting functional tissue therapeutics and disease models using bioprinting.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Polbionica social profiles
Digital presencePolbionica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Polbionica leadership team
Management profileNumber of profiles
Profiles3 records
Polbionica funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Polbionica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Polbionica
What does Polbionica do?
Polbionica develops and manufactures a vertically integrated ecosystem for 3D bioprinting, including proprietary bioink lines (TintBionic, CleanCure, Printiss), laboratory devices (ResearchLine bioreactor, BionicCure UV-Vis lamp, LAP photoinitiator), recombinant proteins (p-SE17, p-RE15), and 3D bioprinting services for tissue/organoid fabrication. Its flagship program is the Bionic Pancreas-ATMP, a fully vascularized bioprinted organ targeting type 1 diabetes and chronic pancreatitis. Products are manufactured under ISO 13485 quality management for researchers, clinicians, and pharmaceutical customers.
Is Polbionica a public or private company?
Polbionica is a private company. It is classified as unknown and is currently operating.
When was Polbionica founded?
Polbionica was founded in 2019. It employs 11 to 50 people.
Where is Polbionica based?
Polbionica is headquartered in Zielona Góra, Poland, in the Europe region.
How does Polbionica make money?
Four revenue lines are on record. Bioinks and Biomaterials Sales are the primary driver. The others are laboratory Devices Sales, 3D Bioprinting Services and bionic Pancreas-ATMP Therapeutic Development.
Who are Polbionica's main competitors?
Emerging players on record are TissUse, Cyfuse Biomedical, Pandorum Technologies and Modern Meadow. Direct peers are CollPlant Biotechnologies, RegenHU, BICO (CELLINK), Aspect Biosystems, Advanced BioMatrix and Organovo.
Does Polbionica have an API?
No public API is recorded for Polbionica.
What industry is Polbionica in?
Polbionica's product category is 3D Bioprinting & Tissue Engineering. Its primary akta.pro industry code is HLAAAGAC, 3D Bioprinting & Biofabrication, with a secondary code of IMAAAAAG, Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware). Its NAICS code is 325414 and its SIC code is 2836.